CNO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CNO Financial Group is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has some constructive signals, including bullish moving averages and a favorable analyst upgrade tied to long-term-care performance, but momentum is weakening short term and options sentiment is mixed. Since there is no strong proprietary buy signal and no recent catalyst in the news, the best call is to hold rather than buy aggressively at this moment.
CNO is trading at 51.51 after closing below the previous close of 52.43, indicating short-term softness. The moving averages are bullish with SMA_5 > SMA_20 > SMA_200, which supports the broader trend, but the MACD histogram is negative and expanding, showing fading momentum. RSI_6 at 62.9 is neutral-to-mildly bullish, not overbought. Price is sitting below R1 at 52.78 and near pivot support at 51.85, with S1 at 50.92 as the next key support. Overall trend is positive on a longer horizon, but near-term price action is not strong enough to call it a clean entry.
Evercore ISI upgraded CNO to In Line from Underperform and raised its target to $48, citing favorable long-term-care statutory analysis and best underlying performance in the peer group. Bullish moving-average alignment supports the longer-term trend. The similar-pattern stock trend data also suggests modest upside probabilities over the next day and week.
There was no news in the last week, so there is no fresh catalyst to drive immediate acceleration. No recent insider, hedge fund, or congress trading activity supports a bullish conviction.
Latest quarter financials were not available due to data error, so there is no reliable quarterly revenue or earnings breakdown to assess. Because the latest quarter season is missing, I cannot confirm current growth trends from the provided financial snapshot.
Analyst tone has improved recently but remains cautious overall. On 2026-06-01, Evercore ISI upgraded CNO to In Line from Underperform and raised its target to $48, citing favorable long-term-care results. On 2026-05-05, Keefe Bruyette raised its target to $50 from $46 and kept a Market Perform rating after Q1 earnings. Wall Street’s pros view: better-than-expected long-term-care fundamentals and improving model assumptions. Cons view: ratings remain neutral, not bullish, and targets are below the current market price, suggesting limited upside from here.
